Objectives: Tenofovir disoproxil fumarate (TDF) may cause renal tubular dysfunction (RTD) and reduce bone mineral density (BMD). We examined the relationship between RTD and BMD in TDF-exposed HIV-positive men.
Introduction
Tenofovir disoproxil fumarate (TDF) is a preferred treatment option for HIV-1 infection and one of the most widely prescribed antiretrovirals [1] . Although TDF has a favourable safety record, a small proportion of patients develop severe renal tubular disease (Fanconi syndrome) [2] . Fanconi syndrome is characterised by glycosuria, phosphate wasting and markedly increased urinary concentrations of low molecular weight proteins (LMWP), and may be accompanied by bone pain, osteomalacia and fragility fractures [3] [4] [5] [6] . TDF exposure may cause or worsen renal tubular dysfunction (RTD), a lesser derangement of renal tubular function [7] [8] [9] [10] . RTD is typically asymptomatic, nonprogressive and nontreatment limiting, and characterized by mild-to-moderate increases in urinary LMWP concentration and variable manifestations of impaired reabsorption of phosphate, urate, glucose and other solutes [11] . Using variable definitions, RTD has been reported in 10-22% of HIV-positive patients receiving TDF [12] [13] [14] .
TDF has an adverse effect on bone mineral density (BMD) [15] . Patients initiating TDF-containing regimens experience greater reductions in BMD compared with those initiating non-TDF containing regimens [16, 17] . In addition, switching to a TDF-containing regimen is associated with reductions in BMD [18] [19] [20] , and discontinuing TDF with improvements in BMD [21] . Preliminary evidence suggests that TDF-associated BMD reductions may translate into increased fracture risk [22] .
It remains unclear whether subclinical RTD is associated with altered bone homeostasis and/or reductions in BMD. In this cross-sectional study, we examined the relationship between RTD, bone turnover and BMD in a cohort of TDF-exposed HIV-positive men.
Methods
Data were drawn from a BMD study in HIV-positive men. Individuals had been randomly selected using a randomization table from a single HIV outpatient clinic in Brighton, UK [23] . At the baseline study visit, biometrics including height, weight and blood pressure were measured. A self-completed questionnaire evaluated medical history and lifestyle factors including history of fragility fracture, exposure to drugs associated with bone metabolism (including inhaled, oral and anabolic steroids), comorbidities associated with bone loss or renal impairment, current alcohol use, smoking status and levels of exercise. Demographics and HIV parameters including age, ethnicity, risk factors for HIV acquisition, hepatitis B and C coinfection, time since HIV diagnosis, current and nadir CD4 þ cell count, prior AIDS diagnoses, current HIV viral load, time since initiating antiretroviral therapy, current exposure to TDF and protease inhibitors and length of exposure to TDF and protease inhibitors were obtained from the clinic database. As the relationship between RTD and bone is most relevant to patients with current TDF exposure, analyses were restricted to those reporting current TDF use.
Plasma creatinine, phosphate (PO 4 ) and alkaline phosphatase (ALP) concentrations were measured on fasting blood samples. Additional aliquots were frozen at À808 and analysed for total 25-hydroxy vitamin D, parathyroid hormone, type 1 collagen cross-linked C-telopeptide (CTX, a marker of bone resorption, Uscn Life Science Inc., Wuhan, China), and procollagen type 1 N-terminal propeptide (P1NP, a marker of bone formation, Uscn Life Science Inc). Fasting urine samples were analysed for protein-creatinine ratio (PCR) and for quantification of urinary phosphate; an aliquot was frozen at À808 for urinary retinol-binding protein (RBP, a LMWP) concentrations [DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay measurement platform) monoclonal antibody assay, Cambridge, UK]. The lower limit of detection was less than 1.0 mg/l [24] and 98% of samples were within measuring range of the assay. Dual energy X-ray absorptiometry (DXA) measurements were obtained using the GE Healthcare Lunar iDXA bone densitometer (GE Healthcare, Madison, Wisconsin, USA). BMD (expressed in g/cm 2 ) of the lumbar spine (L1-L4 composite), the nondominant total hip and the nondominant neck of femur (NOF) were used for analysis.
Definitions
The Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) formula was used to calculate estimated glomerular filtration rate (eGFR) [25] . eGFR was considered both as a continuous variable, and categorically with eGFR more than 90, 75-89 and less than 75 ml/min per 1.73m 2 (because of a small number of patients with eGFR <60). Hypertension was defined as a blood pressure more than 140/90 mmHg. Renal tubular function was assessed by retinol-binding protein/creatinine ratio (RBPCR) and by fractional excretion of phosphate (FEPO 4 ) using the following equation: (urine PO 4 /serum creatinine)/(serum PO 4 /urine creatinine). Patients were considered to have RTD if their RBPCR was above the laboratory upper limit of normal (ULN, 2.93 mg/mmol [24] ); these patients were stratified into those with RBPCR 1-5 Â ULN and more than 5 Â ULN (>14.65 mg/mmol). Patients were also considered to have RTD if they had evidence of phosphate wasting as defined by a fasting FEPO 4 more than 20% in the presence of hypophosphataemia (plasma PO 4 <0.8 mmol/l).
Statistical methods
Variables were transformed where appropriate to approximate to a normal distribution. Factors associated with raised RBPCR and phosphate wasting were examined categorically using multivariate logistic regression with forward stepwise inclusion of variables with P < 0.1. The relationship between RBPCR, FEPO 4 , bone biomarkers and BMD (all as continuous variables; RBPCR also as a categorical variable) was examined using correlation coefficients, and where possible, multivariate linear regression. Assumptions were tested graphically. Exposures, confounders and interactions were chosen a priori on the basis of biological plausibility as well as a significant association in univariate analysis with P < 0.1. Data were complete or near complete for the majority of cases. Whole-case analysis was used to deal with missing data.
Results

Cohort description
A total of 293 HIV-positive men were eligible for inclusion. The mean (SD) age was 47.7 (8.9) years, 94.2% were of White ethnicity and 92.2% had acquired HIV through sex with men (Table 1) . They had been diagnosed HIV-positive for a median (interquartile range) of 9.2 (4.9, 15.0) years and had received TDF for a median of 2.1 (1.2, 4.2) years. In 117 (39.9%) patients, TDF was coadministered with a protease inhibitor (55.6% darunavir/ritonavir, 29.9% atazanavir/ritonavir and 14.5% lopinavir/ritonavir). Almost all had an undetectable HIV viral load. The mean (SD) eGFR was 92.8 (16.6) ml/min per 1.73m 2 . Overall, 3.1% had moderate or severe proteinuria (PCR >50 mg/mmol), 22.5% had RBPCRdefined RTD (16.0% with RBPCR 1-5 Â ULN, 6.5% with RBPCR >5 Â ULN) and 12.3% had FEPO 4defined RTD. The mean (SD) BMD was 1.13 (0.14), 0.99 (0.13) and 0.94 (0.12) g/cm 2 at the lumbar spine, total hip and NOF, respectively.
Factors associated with renal tubular dysfunction
A statistically significant correlation between RBPCR and FEPO 4 was observed (r 2 0.2, P < 0.0001). No Relationship between renal tubular dysfunction and bone A significant negative correlation was observed between RBPCR and BMD at the spine (b À0.2, P ¼ 0.002), total hip (b À0.1, P ¼ 0.02) and NOF (b À0.1, P ¼ 0.02). By contrast, we found no such correlation between FEPO 4 and BMD at any of the three sites (b À0.006, À0.03 and À0.04, P > 0.5 for the lumbar spine, total hip and NOF, respectively) ( Fig. 1 a-f ).
The relationship between RTD and BMD was further explored using multivariate linear regression ( In univariate linear regression models, we observed no significant association between FEPO 4 (as continuous or categorical variable) and BMD at the spine, total hip or NOF (data not shown). When maximal tubular phosphate reabsorption [26] , an alternative marker to assess renal tubular phosphate handling [26] [27] [28] , was used as a continuous variable, we observed a significant association with spine BMD in univariate analysis; 
Discussion
In HIV-positive men receiving TDF-containing antiretroviral therapy, we observed a significant negative correlation between RBP-defined RTD and BMD of the lumbar spine and the hip. This association remained significant at the spine after adjusting for both HIVassociated and traditional risk factors, and for eGFR as a crude measure of renal function. This study, which included 66 cases of RTD, suggests that RBP-defined RTD is associated with reduced BMD. This is in contrast to a previous study with 11 cases of RTD which found no association between RTD and BMD [29] . Our scatter plots of the correlations between RBPCR and BMD do demonstrate a wide degree of scatter and low correlation coefficients; these results suggest that mild derangement of renal tubular function (RBPCR < 5 Â ULN) appears to have little if any effect on BMD. On the contrary, more severe RTD (which was present in 6.5% of participants) remained associated with reduced BMD after adjusting for confounders, and thus potentially identifies a subgroup of patients at increased risk of bone loss.
The putative mechanism that links RTD to BMD is phosphate wasting [30] . Although RBPCR was correlated with FEPO 4 , we observed no association between this measure of RTD and BMD. The association between RBPCR and FEPO 4 , however, was weak (r 2 ¼ 0.2). The lack of association between FEPO 4 and BMD may relate to the cutoffs used in the present analyses to define phosphate wasting, or suggest that reduced fasting plasma phosphate concentrations may not reliably reflect total body phosphate depletion, a signal for tubular phosphate reabsorption. Our data are consistent with a previous study which found superior specificity of LMWP (b-2 and a-1 microglobulin) compared with FEPO 4 to diagnose RTD [14] , and suggest that concurrent plasma and urine phosphate measurements may be of limited use in identifying patients at greatest riskof TDF-associated bone loss.
Reductions in BMD observed in clinical trials with TDF have been associated with increased bone turnover [16, 19, 20] . In keeping with the study of Calmy et al. [29] , we observed no correlation between RBPCR and markers of either bone resorption or bone formation. This lack of association is somewhat puzzling although the cross-sectional nature of our study may have limited our ability to detect such a relationship. The use of bone turnover markers in clinical practice remains controversial other than to monitor responses to bisphosphonate treatment [31] . It is possible that the mechanisms of TDF-associated initial bone loss are mediated through the parathyroid axis [32] or via a direct effect of TDF on bone [20] . Indeed, the initial reductions in BMD observed with TDF in the ASSERT (Kivexa Vs. Truvada, Both Administered With Efavirenz, In ART-Naive Subjects) study did not correlate with LMWP concentrations [16] . Although these initial reductions in BMD tend to stabilize 1790 AIDS 2015, Vol 29 No 14 after 48 weeks of TDF exposure [16] [17] [18] [19] , the effects of persistent RTD may be masked by the magnitude of the initial BMD decline and only become apparent with chronic TDF exposure.
The strength of the relationship between RBP-defined RTD at the spine vs. the hip may be partly explained by the difference in bone composition at the spine (predominantly trabecular) [33] and hip (predominantly cortical) [34] . The metabolic rate per unit volume bone is higher in trabecular bone, and this may render this type of bone more sensitive to endogenous insults [35] . Consequently, BMD changes may differ between bone sites, and high bone turnover states, such as HIV-associated osteoporosis, may involve trabecular bone at an earlier stage than cortical bone [36] .
The strengths of this study include the large, homogeneous and contemporaneous study population and the use of a robust assay to measure RBP. However, as we studied almost exclusively White men, our observations cannot necessarily be extrapolated to women or those of other ethnicities. Variables determined on questionnaire were not reconciled with medical records and may therefore have been subject to recall and/or overreporting bias. Patients who had permanently stopped TDF after developing renal tubular disease (nine in the parent cohort) were not included in the analyses which may have underestimated the impact of TDF on the renal tubular function. It is also unclear whether other LMWPs or measurements of phosphate excretion, such as 24-h collections, would have rendered similar results.
Although studies have examined the correlation between spot urine phosphate/creatinine ratio and 24-h urine phosphate excretion [37, 38] , the correlation between FEPO 4 and these measurements are unknown. Our crosssectional study design precludes inference of causality, and the clinical significance of the observed BMD reductions remains to be defined. Our observations should be confirmed in more ethnically diverse cohorts and women, and perhaps with a broader panel of tubular biomarkers. Finally, longitudinal studies are required to confirm that the relationship between RBP-defined RTD and reduced BMD, and that TDF discontinuation improves both RTD and BMD.
In conclusion, we observed a negative correlation between RBP-defined RTD and BMD of the spine in HIV-positive patients on TDF-containing antiretroviral therapy. Quantification of RBP may help identify patients who could benefit from TDF discontinuation to preserve BMD and reduce fracture risk.
